Simon Craige

2020-10-12T17:30:01+01:00

Meet The Team

Simon Craige | Toxicologist | ApconiX

Simon Craige

MSc, ERT, DABT

Simon is a European Registered Toxicologist and Diplomate of the American Board of Toxicology with over 15 years of nonclinical and toxicology experience within various pharmaceutical and medical device settings.  Simon has worked within biotech and a number of CROs across a diverse range of therapeutic areas in both Discovery and Development.  His experience includes a variety of therapeutic platforms including small molecules, biologicals, and medical devices.  During his career, he has acted as a single point of contact for the planning and monitoring outsourced studies, interpretation of study results, contingency planning/troubleshooting, report reviewing and authoring of regulatory documents.  Simon’s knowledge, breadth of experience and pragmatic approach aligns perfectly with the toxicologist group in ApconiX as we support our growing client base.

Ruth Roberts
Richard Knight
Dr Mike Morton
Mike Morton

Duncan Armstrong

2020-09-14T17:40:14+01:00

Meet The Team

Dr Duncan Armstrong PhD | Pharmacologist | ApconiX

Dr Duncan Armstrong

PhD

Duncan is an expert pharmacologist with an international reputation in secondary and safety pharmacology, gained over 18 years in drug discovery and development at AstraZeneca and Novartis. Having worked with project teams at all stages of discovery and development across multiple therapy areas, he has a track record of optimising small molecule off-target safety profiles and in understanding and interpreting target-related safety risks. Duncan enjoys bringing his passion for pharmacology to successful collaborative teams.

Ruth Roberts
Richard Knight
Dr Mike Morton
Mike Morton

Karen Burnett

2020-09-14T17:40:46+01:00

Meet The Team

Dr Karin Burnett | Toxicologist | ApconiX

Dr Karin Burnett

PhD, DABT

Karin is a toxicologist with extensive experience of drug safety having worked for a number of pharmaceutical companies including Zeneca, SmithKline Beechams and Shire Pharmaceuticals.  More recently Karin has worked with Public Health England and Imperial College, London (Toxicology Unit) as a scientific writer compiling detailed literature reviews on a wide variety of subjects for the government advisory Committees on Carcinogenicity (COC) and Mutagenicity (COM).  Karin brings depth and breadth of experience gained from the application of toxicology in diverse sectors.

Ruth Roberts
Richard Knight
Dr Mike Morton
Mike Morton

Laurence Bishop

2020-09-14T17:41:14+01:00

Meet The Team

Dr Laurence Bishop | Head of Business Development | ApconiX

Dr Laurence Bishop

PhD

Laurence is an experienced DMPK and toxicological Scientist, with 20 years of non-clinical drug development and chemical experience at medium and large CROs as well as within AstraZeneca. Specialising in Business Development for the last 13 years Laurence combines a passion for appropriate pharmaceutical development and a knowledge of project scientific and commercial needs. he is well placed to support both our customers and Apconix to best deliver non-clinical safety programmes. Laurence has a proven track record for communication, ownership, integrity and delivery, building mutually beneficial and lasting customer relationships.

Ruth Roberts
Richard Knight
Dr Mike Morton
Mike Morton

Kemal Haque

2020-07-13T13:35:37+01:00

Meet The Team

Kemal Haque | ApconiX

Kemal Haque

PhD

Kemal is a toxicologist with 20 years’ experience supporting biopharma projects from early discovery through clinical development. He has experience across different therapeutic areas, target classes, and modalities (small molecule and biologics) and has worked in both small biotech and large pharma organisations. Kemal has a track record of delivering timely, fit-for-purpose toxicology data packages, on budget and successfully devising and executing critical path risk mitigation strategies

Peter Ballard
Annette Zaar
Drug safety
Drug Project Toxicology

Tanya Coleman

2020-09-14T17:45:59+01:00

Meet The Team

Tanya Coleman

PhD

Tanya has more than 20 years’ experience in pharmaceutical project teams as a nonclinical ADME specialist and clinical pharmacologist. She held project and team leader roles at several large pharma companies before becoming an independent consultant.  In these roles, she has supported research teams as well as early and late clinical development projects, with a particular strength in oncology and infection.  Tanya has also led specialist groups in in vitro metabolism and drug transporters.

Damian
Damian Deavall
Richard Knight
Drug safety
Drug Project Toxicology

Sanofi

2020-09-14T17:47:25+01:00

“The target safety evaluation was perfect.  Our toxicologist was very happy with the final document as was the project team.  Not only was the document great, it was delivered on time and the turn-around time for the edits was outstanding.  I have no doubt that we will be using your services in the future.”

James Murray, Toxicologist, Sanofi

Leading Global Pharmaceutical Company

2020-01-23T09:22:46+00:00

“I wanted to let you know that, after including your expert report into the IB, the Health Authority have approved both the IB as well as the clinical protocol amendment switching the contraception method from highly affective to effective, without any further questions or comments.

This is a very good news for the project, and clinical studies can continue as planned. Thank you very much for all your support, it was a great pleasure collaborating with you. I have greatly appreciated your thorough assessment as well as responsive and friendly  manner, and your input made a key difference for the project progression.”

Preclinical Project Manager, Leading Global Pharmaceutical Company

Olivia Turner

2020-09-14T17:53:26+01:00

Meet The Team

Olivia Turner

Industry Placement

Olivia has recently completed her second year studying Biomedical Sciences at Sheffield University. Choosing to take the Physiology and Pharmacology route in her second year, Olivia is currently on a placement year (jointly with ApconiX and Aptus Clinical) to gain greater understanding of drug development and the pharmaceutical industry. She hopes to be able to finish her degree and move straight to studying for a Ph.D. Versatile, enthusiastic and highly adaptive, Olivia is a great addition to the ApconiX office as she learns about the essential role of drug safety in pharmaceuticals as well as what it’s like to be part of a growing company.

William O’Brien
Julie Knight
Home

Andrew Winkley

2020-09-14T17:56:32+01:00

Meet The Team

Andrew Winkley

PhD, DABT

Andrew has over 20 years of drug safety experience in industry at AstraZeneca and Vertex. He has a broad scientific background that includes mechanistic and regulatory toxicology, and biochemistry. His drug development experience covers the complete life cycle of drug development from discovery to late-stage development in several therapeutic areas including orphan indications, neuroscience, pain therapeutics, inflammatory diseases, infectious diseases, and oncology. Andrew has been involved in bringing several candidate molecules to clinical trials and most recently completed an NDA/MAA for a cystic fibrosis drug. Andrew is a highly adaptive project toxicologist who can assimilate and interpret a broad range of data from various disciplines to provide clear guidance to the project team.

Claire Sadler
Target Safety Assessments